RNS Number : 7079T MaxCyte, Inc. 16 November 2023 MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines.
RNS Number : 8538S MaxCyte, Inc. 09 November 2023 MaxCyte announces filing of Form 10-Q for the quarterly period ended September 30, 2023 ROCKVILLE, MD , November 9, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 8496S MaxCyte, Inc. 09 November 2023 MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance ROCKVILLE, MD , November 9, 2023 Ñ MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
RNS Number : 5574S MaxCyte, Inc. 07 November 2023 MaxCyte to Participate in Two Upcoming Investor Conferences Rockville, MD , November 7, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 0789S MaxCyte, Inc. 01 November 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, Maryland - 1 November 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform
RNS Number : 7367O MaxCyte, Inc. 05 October 2023 MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance ROCKVILLE, MD , October 5, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
RNS Number : 4224O MaxCyte, Inc. 02 October 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, Maryland - 2 October 2023: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform
RNS Number : 3508M MaxCyte, Inc. 13 September 2023 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 1986M MaxCyte, Inc. 12 September 2023 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 5613L MaxCyte, Inc. 06 September 2023 MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing ROCKVILLE, MD , September 6, 2023 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
